| Literature DB >> 33898776 |
Emilia Palmér1, Anna Karlsson1,2, Fredrik Nordström1,2, Karin Petruson3, Carl Siversson4,5, Maria Ljungberg1,2, Maja Sohlin1,2.
Abstract
BACKGROUND ANDEntities:
Keywords: Convolutional neural network; Head and neck; MRI only; Pseudo CT; Synthetic CT; Treatment planning
Year: 2021 PMID: 33898776 PMCID: PMC8058030 DOI: 10.1016/j.phro.2020.12.007
Source DB: PubMed Journal: Phys Imaging Radiat Oncol ISSN: 2405-6316
Patients characteristics and prescribed dose.
| Characteristic | Patients | ||
|---|---|---|---|
| No | % | ||
| Sex | Male | 28 | 64 |
| Female | 16 | 36 | |
| Age, years | Mean | 67 | |
| Range | 39–85 | ||
| Cancer site | Oral | 10 | 23 |
| Oropharynx | 12 | 27 | |
| Hypopharynx/Larynx | 9 | 20 | |
| Epipharynx | 1 | 2 | |
| Parotic gland | 7 | 16 | |
| Outer ear canal/Skin | 3 | 7 | |
| Unknown primary head and neck | 2 | 5 | |
| Prescribed dose to primary tumour | 68 (2 Gy/fx) Gy | 3 | 7 |
| 54 (3 Gy/fx) Gy | 2 | 5 | |
| 46 (2 Gy/fx) Gy | 1 | 2 | |
| Prescribed dose to primary tumour and lymph nodes | 68 Gy + 68 (2 Gy/fx) | 11 | 25 |
| 68 Gy + 52.7 (1.55 Gy/fx) Gy | 27 | 61 | |
Evaluated dose volume histogram (DVH) parameters, mean relative absorbed dose difference in percent and difference in absolute absorbed dose.
| DVH parameter | Relative absorbed dose Mean ± 1sd (%) | Absolute absorbed dose Mean ± 1sd (Gy) | No. of included volumes |
|---|---|---|---|
| PTVT Dmean | −0.1 ± 0.2 | −0.1 ± 0.1 | 44 |
| PTVT D98% | −0.0 ± 0.4 | −0.0 ± 0.2 | 44 |
| PTVT D2% | 0.0 ± 0.4 | 0.0 ± 0.3 | 44 |
| PTVN D98% | −0.1 ± 0.2 | −0.1 ± 0.1 | 27 |
| PRV Spinal cord D2% | −0.2 ± 0.2 | −0.1 ± 0.1 | 44 |
| Parotid Sin Dmean | −0.2 ± 0.5 | −0.1 ± 0.1 | 36 |
| Parotid Dx Dmean | −0.2 ± 0.4 | −0.0 ± 0.1 | 38 |
| Larynx Dmean | −0.1 ± 0.2 | −0.0 ± 0.1 | 40 |
| Upper esophageal sphincter Dmean | −0.1 ± 0.4 | −0.1 ± 0.1 | 37 |
| Submandibular glans Sin Dmean | −0.3 ± 0.4 | −0.1 ± 0.1 | 32 |
| Submandibular glans Dx Dmean | −0.2 ± 0.3 | −0.1 ± 0.1 | 38 |
| Body D2% | −0.1 ± 0.3 | −0.1 ± 0.2 | 44 |
Abbreviations: planning target volume primary tumour (PTVT), absorbed dose (D), planning target volume lymph nodes (PTVN), planning organ at risk volume (PRV)
Dose delivered using simultaneous integrated boost
Organ surgically removed pretreatment or excluded
Fig. 1The magnetic resonance image (MRI), generated synthetic computed tomography (sCT) and computed tomography (CT) data, as well as corresponding Hounsfield units (HU) difference (sCT-CT), representing the A) maximum (102 HU) and B) minimum (47 HU) mean absolute error for overall body.
Fig. 2A) Mean water equivalent depths (WED) for all computed tomography (CT) data sets (blue) and corresponding synthetic CT (sCT) (red), and B) mean WED difference (light blue) and the corresponding standard deviation (sd) (dark blue) for 44 paired data sets as a function of degree, presented for three regions; Th1-C7 (left), mid mandible (middle) and mid nose (right). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3The magnetic resonance image (MRI), generated synthetic computed tomography (sCT) data with minor dental artefacts, computed tomography (CT) data with severe dental artifacts and difference between sCT and CT in Hounsfield units (HU).
Fig. 4Relative absorbed dose difference for the evaluated dose volume histogram (DVH) parameters comparing synthetic computed tomography (sCT) and computed tomography (CT) dose distributions for 44 paired data sets. Abbreviation: planning target volume primary tumour (PTVT), absorbed dose (D), planning target volume lymph nodes (PTVN), planning organ at risk volume (PRV), Upper esophageal sphincter (Upper eso. sph), Submandibular glans (Submandib.)